We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
Cap. Flow
-$139M
Cap. Flow %
-25.42%
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$11.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.51M
3
UTHR icon
United Therapeutics
UTHR
+$8.13M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.75M
5
ALT icon
Altimmune
ALT
+$5.53M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$21M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.33M
3
SAGE
Sage Therapeutics
SAGE
+$8.38M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.11M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 43.2%
2 Technology 0.14%
3 Consumer Staples 0.03%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
76
Chemomab Therapeutics
CMMB
$10.7M
$992K 0.18%
67,026
– –
ARDX icon
77
Ardelyx
ARDX
$1.24B
$991K 0.18%
+1,680,552
New +$1.24M
ANEB
78
DELISTED
Anebulo Pharmaceuticals
ANEB
$942K 0.17%
181,199
– –
FNCH
79
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$938K 0.17%
11,017
– –
BLU
80
CALL
DELISTED
BELLUS Health Inc.
BLU
$924K 0.17%
+100,000
New +$818K
CMRX
81
DELISTED
Chimerix, Inc.
CMRX
$917K 0.17%
441,203
-400,000
-48% -$1.28M
AUTL
82
Autolus Therapeutics
AUTL
$389M
$912K 0.17%
322,217
-50,000
-13% -$152K
TCDA
83
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
$899K 0.16%
92,900
– –
FULC icon
84
CALL
Fulcrum Therapeutics
FULC
$241M
$893K 0.16%
+182,200
New +$1.78M
ELDN icon
85
Eledon Pharmaceuticals
ELDN
$255M
$884K 0.16%
362,537
– –
RIGL icon
86
Rigel Pharmaceuticals
RIGL
$723M
$794K 0.14%
70,277
-143,436
-67% -$2.88M
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
$761K 0.14%
422,339
-350,000
-45% -$516K
AYLA
88
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$759K 0.14%
697,316
-11,067
-2% -$25.3K
TARA icon
89
Protara Therapeutics
TARA
$214M
$756K 0.14%
257,853
-38,573
-13% -$141K
RNTX
90
Rein Therapeutics
RNTX
$64.8M
$752K 0.14%
144,616
-488
-0.3% -$4.48K
IRON icon
91
Disc Medicine
IRON
$2.81B
$749K 0.14%
14,770
– –
BCLI
92
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$698K 0.13%
16,895
-3,382
-17% -$152K
PRDS
93
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$687K 0.13%
223,934
-100,000
-31% -$611K
RETA
94
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$632K 0.12%
20,805
-66,100
-76% -$1.97M
BLCM
95
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$617K 0.11%
523,348
– –
CFRX
96
PUT
DELISTED
ContraFect Corporation
CFRX
$615K 0.11%
+2,500
New +$706K
TAOX
97
Tao Synergies Inc
TAOX
$24.1M
$614K 0.11%
4,848
-1,281
-21% -$189K
LONA
98
PUT
LeonaBio Inc
LONA
$66.1M
$609K 0.11%
19,950
-50
-0.3% -$4.58K
RCOR
99
DELISTED
Renovacor, Inc.
RCOR
$595K 0.11%
293,283
-50,000
-15% -$132K
CNTB
100
Connect Biopharma Holdings
CNTB
$129M
$591K 0.11%
677,859
– –
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.

  • Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
  • Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
  • Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
  • Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
  • Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
  • Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
  • Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.